Course of intrahospital coronavirus infection (COVID-19) against the background of preventive and curative administration of peptide immunotropic drugs as part of complex therapy
| Autor: | Victor V. Rudenko, V. S. Smirnov, Sergey V. Petlenko |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Pharmacy Formulas. 2:8-13 |
| ISSN: | 2713-1602 2713-153X |
| DOI: | 10.17816/phf43135 |
| Popis: | Due to the lack of COVID-19 specific preventive measures with a prophylactic and therapeutic (as part of complex therapy) purpose, various drugs were used as humanitarian aid from manufacturing companies to prevent influenza and SARS in St. Petersburg hospitals. The study of Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden patient treatment shows the possibility of using drugs containing a synthetic regulatory thymus peptide (L-glutamine-L-tryptophan-thymogen) as an active ingredient in a patient with an in-hospital coronavirus infection. This compound has a number of extra- and intracellular immunotropic effects of key importance in the pathogenesis of respiratory viral infections, including coronavirus etiology. The components have an indirect antiviral effect against acute respiratory viral infections, comprising COVID-19. This led to the use of drugs containing thymogen for the prevention and treatment of COVID-19. The use of immunotropic agents promoted the rapid involution in the patient of clinical, laboratory and instrumental (radiological) signs of the disease and its uncomplicated course both in the primary infection and the development of superinfection cases. The study has shown that the use for the prevention and treatment (as part of complex therapy) of drugs with immunomodulatory activity, as well as those capable of affecting various links in the pathogenesis of pulmonary lesions in coronavirus infection, seems to be highly relevant and justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|